Von professionellen Übersetzern, Unternehmen, Websites und kostenlos verfügbaren Übersetzungsdatenbanken.
the non-linearity is likely due to a saturable target-mediated elimination pathway of importance at low concentrations.
in-nuqqas ta’ linearità x’aktarx huwa minħabba rotta ta’ eliminazzjoni medjata minn mira saturabbli ta’ importanza f’konċentrazzjonijiet baxxi.
based on in vitro and in vivo studies, raltegravir is eliminated mainly by metabolism via a ugt1a1- mediated glucuronidation pathway.
fuq il-bażi ta’ studji in vitro u in vivo, raltegravir huwa eliminat prinċipalment permezz ta’ metaboliżmu minn ġo mogħdija ta’ glukuronidazzjoni mwettqa minn ugt1a1.
micafungin has a low potential for interactions with medicines metabolised via cyp3a mediated pathways.
micafungin għandu potenzjal baxx ta’ interazzjoni ma’ mediċini metabolizzati permezz ta’ proċessi medjati minn cyp3a.
palonosetron is eliminated from the body through both renal excretion and metabolic pathways, with the latter mediated via multiple cyp enzymes.
palonosetron jiġi eliminat mill-ġisem permezz kemm ta’ tneħħija mill- kliewi kif ukoll minn passaġġi metaboliċi, b’dawn tal-aħħar li jkunu medjati permezz ta’ enzimi multipli ta’ cyp.
cabazitaxel did not inhibit in vitro the major biotransformation pathway of warfarin into 7-hydroxywarfarin, which is mediated by cyp2c9.
in vitro, cabazitaxel ma kkawżax l-inibizzjoni tal-mod l-aktar importanti li biha ssir il- bijotrasformazzjoni ta’ warfarin f’7-hydroxywarfarin, li ssir permezz ta’ cyp2c9.
based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for cyp450 mediated interactions involving tenofovir with other medicinal products is low.
ibbażat fuq riżultati ta ’ esperimenti in vitro u r- rotta ta ’ l- eliminazzjoni magħrufa ta ’ tenofovir, il - potenzjal għall- interazzjoni medjata minn cyp450 li tinvolvi tenofovir ma ’ prodotti mediċiali oħra hija baxxa.
brivaracetam is cleared by multiple pathways including renal excretion, non-cyp-mediated hydrolysis and cyp-mediated oxidations.
brivaracetam huwa mneħħi b’modi differenti inkluż eskrezzjoni mill-kliewi, idroliżi mhux medjat minn cyp u oxidazzjonijiet medjati minn cyp.
based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for cyp450-mediated interactions involving tenofovir with other medicinal products is low.
ibbażat fuq riżultati ta’ esperimenti in vitro u r-rotta ta’ l-eliminazzjoni magħrufa ta’ tenofovir, il- potenzjal għall-interazzjonijiet medjata minn cyp450 li tinvolvi tenofovir ma’ prodotti mediċiali oħra hija baxxa.
based on non-cyp-mediated elimination pathways for lorazepam, no effect on plasma concentrations is expected upon co-administration with genvoya.
ibbażat fuq passaġġi ta’ eliminazzjoni mhux medjati minn cyp għal lorazepam, l-ebda effett fuq il-konċentrazzjonijiet fil-plażma mhu mistenni bl-għoti flimkien ma’ genvoya.
exenatide has been shown to bind to and activate the known human glp-1 receptor in vitro, its mechanism of action mediated by cyclic amp and/or other intracellular signalling pathways.
Ġie muri li in vitro exenatide jingħaqad u jattiva r- riċettur glp-1 uman u l-mekkaniżmu ta’ azzjoni tiegħu huwa permezz tal-amp ċikliku u/jew mekkaniżmi oħra ta’ sinjali intraċellulari.